文献速递垂体与肾上腺疾病肥胖与代谢综合征糖尿病

肾上腺库欣综合征的流行病学与共病:一项全国性队列研究

Epidemiology and Comorbidity of Adrenal Cushing Syndrome: A Nationwide Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该回顾性全国队列研究基于韩国医保数据库,纳入2002至2017年1199例肾上腺库欣综合征患者。结果显示粗发病率为1.51/百万人年,年龄标化发病率为1.27/百万人年。良性肾上腺库欣综合征总体标准化死亡比为3.0(95%CI 2.4-3.7),恶性为13.1(95%CI 7.6-18.6)。患者术前术后均高发冠心病、卒中、代谢疾病和抑郁,提示肾上腺切除术后仍存在显著残余风险。

要点

  • 肾上腺库欣综合征粗发病率为1.51/百万人年,年龄标化发病率为1.27/百万人年。
  • 良性肾上腺库欣综合征标准化死亡比为3.0(95%CI 2.4-3.7),恶性为13.1(95%CI 7.6-18.6)。
  • 术后糖皮质激素替代治疗中位时间为10.1个月,泼尼松龙占66.6%,氢化可的松占22.4%。

核心结论

  • 肾上腺库欣综合征患者即使接受肾上腺切除术,仍存在多种共病的显著残余风险,需要细致的术后管理。

研究设计与样本

  • 回顾性队列研究,基于韩国全国医保索赔数据库,纳入2002至2017年1199例接受肾上腺切除术且诊断为库欣综合征、无垂体手术史的患者。

主要发现

  • 2002至2017年韩国共有1199例新发肾上腺库欣综合征患者,其中72例为肾上腺皮质癌(恶性肾上腺库欣综合征)。
  • 粗发病率和年龄标化发病率分别为1.51/百万人年和1.27/百万人年。
  • 良性肾上腺库欣综合征总体标准化死亡比为3.0(95%CI 2.4-3.7),恶性为13.1(95%CI 7.6-18.6)。
  • 患者术前和术后诊断冠心病、卒中、代谢疾病和抑郁的比例相似,提示肾上腺切除术后仍有显著残余风险。
  • 术后糖皮质激素替代治疗中位时间为10.1个月,主要类型为泼尼松龙(66.6%)和氢化可的松(22.4%)。

临床怎么用

  • 对肾上腺库欣综合征患者应进行长期共病监测,包括冠心病、卒中、代谢疾病和抑郁,术后仍需持续关注。
  • 术后糖皮质激素替代治疗需根据患者情况个体化调整,中位疗程约10.1个月,常用泼尼松龙或氢化可的松。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adrenal Cushing syndrome (CS) is a major subtype of CS and has a high surgical cure rate. However, only a few studies have investigated the epidemiology and long-term outcomes of adrenal CS. OBJECTIVE: We aimed to investigate the nationwide epidemiology, long-term prognosis, and postoperative glucocorticoid replacement therapies of adrenal CS in Korea. DESIGN: Retrospective cohort study. SETTING: A nationwide claim database. PATIENTS: Adrenal CS patients who were defined as having undergone adrenalectomy, a diagnosis code of CS, and not having pituitary gland surgery. MAIN OUTCOME MEASURES: Crude incidence and age-standardized incidence rates, long-term mortality, comorbidities diagnosed preoperatively or developed postoperatively, and the pattern of postoperative glucocorticoid replacement therapy. RESULTS: From 2002 to 2017, there were a total of 1199 new adrenal CS patients, including 72 patients with adrenocortical carcinoma (malignant adrenal CS), in Korea. The crude and age-standardized incidence rates were 1.51 and 1.27 per million person-years, respectively. The overall standardized mortality ratio was 3.0 (95% confidence interval [CI], 2.4-3.7) for benign adrenal CS and 13.1 (95% CI, 7.6-18.6) for malignant adrenal CS. Adrenal CS patients had a high risk of having coronary artery disease, stroke, metabolic diseases, and depression. A similar proportion of patients were diagnosed with these comorbidities both preoperatively and postoperatively, suggesting a significant residual risk even after adrenalectomy. The median time of postoperative glucocorticoid replacement therapy was 10.1 months, and the major types of glucocorticoids used were prednisolone (66.6%) and hydrocortisone (22.4%). CONCLUSIONS: Adrenal CS is associated with multiple comorbidities even after treatment, which necessitates meticulous postoperative care.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ahn CH, Kim JH, Park MY, et al. Epidemiology and Comorbidity of Adrenal Cushing Syndrome: A Nationwide Cohort Study. J Clin Endocrinol Metab. 2021. PMID: 33075802. doi:10.1210/clinem/dgaa752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。